Drugs / CD5/CD7 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06420076 | Jul 2024 → Dec 2025 overdue | T-cell childhood acute lymphocytic leukemia, T-cell prolymphocytic leukemia, central nervous system non-hodgkin lymphoma | Essen Biotech | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD5/CD7 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06420076 ↗ |
| Modality | Cell therapy | “The intervention in this clinical trial involves a novel approach using CD5/CD7 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy.” NCT06420076 ↗ |
| Route | Intravenous | “Subsequently, patients will receive CD5/CD7 CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0.” NCT06420076 ↗ |
| Target | CD5 | “Sequential CAR-T Cells Targeting CD5/CD7” NCT06420076 ↗ |
| Target | CD7 | “Sequential CAR-T Cells Targeting CD5/CD7” NCT06420076 ↗ |